GAIL's Q4 profit falls 6% to Rs 2,049 cr on weaker gas marketing, petchem margins
GAIL (India) Ltd has reported a 6% year-on-year decline in profit to ₹2,049 crore for the fourth quarter, primarily due to losses in its petrochemical business.
ADVERTISEMENT Revenue from operations rose 10% to ₹35,707 crore in the January–March quarter. The company's operating profit from its natural gas transmission business expanded during the quarter, but lower profit from gas marketing and a loss in petrochemicals weighed on overall earnings.
For the full year 2024–25, revenue rose 5% to ₹1,37,288 crore, while profit climbed 28% to ₹11,312 crore. All business segments reported higher operating profits during the year, except petrochemicals, where losses narrowed compared to the previous year.
Natural gas sales and transmission volumes are expected to grow by 6–8% in the current year, GAIL Chairman Sandeep Kumar Gupta told a news conference. Henry Hub prices—the U.S. benchmark for natural gas—may remain around $3.5–4 per MMBtu in the short to medium term, he said.GAIL has declared a final dividend of Re 1 per equity share. Its shares closed 2% lower at ₹183.95 apiece on Tuesday, when the benchmark BSE Sensex ended 1.55% lower.Last month, GAIL floated a tender to acquire up to a 26% equity stake in a U.S. LNG project, combined with the offtake of one million tonnes per year of LNG for 15 years. The company has received responses from five parties and is evaluating the proposals, said Rajeev Singhal, Director (Business Development).
ADVERTISEMENT For the first time, GAIL expects to use its gas import terminal at Dabhol during the monsoon this year, following the completion of a breakwater facility. Until now, the terminal had remained shut during the monsoon season.On Tuesday, GAIL's board approved the transfer of its city gas business in six licensed areas—including Varanasi, Patna, Ranchi, and Bhubaneswar—to its wholly owned subsidiary, GAIL Gas Ltd, for improved business synergy and operational efficiency, Gupta said.
ADVERTISEMENT During the January–March quarter, GAIL reported an operating loss of ₹158 crore in the petrochemical business, compared to a profit of ₹262 crore in the same period last year, due to a sharp rise in input costs—primarily imported natural gas—which could not be fully offset by product price hikes.Operating profit from the natural gas marketing business also declined to ₹1,204 crore during the quarter, from ₹1,389 crore a year earlier, while profit from gas transmission rose to ₹1,268 crore from ₹982 crore.
ADVERTISEMENT
(You can now subscribe to our ETMarkets WhatsApp channel)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Glenmark Pharma rises 2% as company to launch blood cancer treatment drug
Glenmark Pharma share price rose 1.7 per cent in trade on Tuesday, June 10, 2025, logging an intraday high at ₹1,626.6 per share on BSE. At 10:30 AM, Glenmark Pharma shares were trading 1.56 per cent higher at ₹1,623.35 per share on the BSE. In comparison, the BSE Sensex was up 0.05 per cent at 82,482.52. The company's market capitalisation stood at ₹45,811.07 crore. Its 52-week high was at ₹1,830.05 per share and 52-week low was at ₹1,176 per share. In the past one year, Glenmark shares have gained 33 per cent as compared to Sensex's rise of around 8 per cent. What is boosting rally in Glenmark Pharma shares? The stock gained after the company announced the upcoming launch of zanubrutinib, under the brand name Brukinsa in India. Brukinsa, developed by global oncology company BeOne Medicines (formerly BeiGene), is an orally available Bruton's tyrosine kinase (BTK) inhibitor designed to treat multiple types of B-cell blood cancers. It is the first and only BTK inhibitor approved in India for five types of B-cell malignancies. According to the filing, Brukinsa has already been approved in more than 70 countries, with clinical efficacy demonstrated through trials such as ALPINE, ASPEN and SEQUOIA. Its entry into the Indian market addresses a critical need for new and effective blood cancer treatments. The drug offers a unique pharmacological profile with high response rates and durable disease control across multiple B-cell malignancies. It allows a flexible dosing schedule—once or twice daily—tailored to patient needs. In the ALPINE trial for relapsed or refractory chronic lymphocytic leukaemia (CLL), Brukinsa showed a lower incidence of serious cardiac side effects compared to ibrutinib, a widely used targeted therapy. Fewer patients discontinued Brukinsa due to heart-related complications. About Glenmark Pharmaceuticals Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. About BeOne Medicines BeOne Medicines, formerly known as BeiGene, is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide.
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Here's why Jana Small Finance Bank share is buzzing in trade on June 10
Jana Small Finance Bank share price: Jana Small Finance Bank (Jana SFB) share price was buzzing in trade on Tuesday, June 10, 2025, with the stock rising up to 6.38 per cent to hit an intraday high of ₹552.90 per share. At 10:06 AM, Jana SFB share price was trading 2.42 per cent higher at ₹532.30 per share. In comparison, BSE Sensex was trading 0.03 per cent higher at 82,469.38 levels. What sparked a rally in Jana SFB share price today? Jana SFB shares advanced after the lender submitted an application to the Reserve Bank of India (RBI), seeking its approval to convert from a Small Finance Bank to a Universal Bank. In an exchange filing, Jana SFB said, 'We wish to inform you that the Bank has submitted its application to the Reserve Bank of India (RBI) today i.e. June 9, 2025 seeking approval for voluntary transition from a Small Finance Bank to a Universal Bank.' Jana SFB Q4 results Adjusted profit after tax (PAT) zoomed 33 per cent year-on-year (Y-o-Y ) to ₹779 crore in FY25, from ₹587 crore in FY24. The Asset AUM stood at ₹29,545 crore, up 19 per cent Y-o-Y with 70 per cent share of secured assets. Its secured assets grew 40 per cent and unsecured de-growth was 11 per cent for FY25. Its total deposits came in at ₹29,120 crore, up 29 per cent Y-o-Y. On Q4 show, Ajay Kanwal, MD and CEO of Jana Small Finance Bank had said, 'With this year's result, we have met the required conditions of GNPA<3 per cent and NNPA<1 per cent for 2 consecutive years. Thus, we will be applying for a Universal Banking Licence in this quarter. The Bank's performance during FY25 has been tremendous given the challenges in the MFI industry and tight liquidity faced during the year. However, being true to our strategy, we grew our Secured book by 40 per cent Y-o-Y, which is now at 70 per cent of AUM. Our deposits have grown at a solid 29 per cent, significantly over pacing the industry. Given that MFI stress peak has past last year, we are looking forward to a solid year ahead.' About Jana SFB Jana Small Finance Bank, a scheduled commercial bank and the fourth-largest Small Finance Bank in India, brings over 16 years of lending experience and serves more than 12 million customers. Established as a bank in March 2018, it has evolved from its roots as an NBFC-MFI into a digitally driven institution with a nationwide footprint across 23 states and 2 union territories through 802 branches. Today, around 70 per cent of its lending portfolio is secured, primarily backed by mortgages. Jana has built a rapidly expanding retail deposit base, underpinned by strong brand recognition and a focus on customer service. Its leadership team brings an average of 27 years of industry experience, supported by a well-rounded and respected Board.
New Indian Express
an hour ago
- New Indian Express
Rupee rises 8 paise to ₹85.58 against the dollar on Tuesday early trade
CHENNAI: The Indian rupee opened on a positive note, appreciating by 8 paise to ₹85.58 against the US dollar in early trade. This uptick was attributed to a positive opening in domestic equity markets and robust foreign capital inflows, reflecting investor confidence in the Indian economy. Key factors influencing the rupee's movement Domestic Equity Market Performance: The positive sentiment in Indian equities, with indices like the Nifty 50 and BSE Sensex showing gains, contributed to the rupee's strength. Foreign Capital Inflows: Strong inflows of foreign capital into Indian markets provided support to the rupee, indicating investor confidence.
